SPONSOR
The First Affiliated Hospital with Nanjing Medical University
Total Trials
14
Recruiting
14
Phases
Phase 2, EARLY_Phase 1
Conditions studied: Gastric AdenocarcinomaSolid TumorRelapsed or Refractory (R/R) Primary Central Nervous System LymphomaRenal TumorProne PositionRobotic Assisted Partial NephrectomyAllergic RhinitisLeptomeningeal Metastasis of HER2-positive Breast CancerArteriovenous Malformation of Central Nervous SystemAneurysm, Ruptured
The First Affiliated Hospital with Nanjing Medical University is a clinical research sponsor with 14 registered studies on ClinicalTrials.gov, of which 14 are actively recruiting participants. Research covers conditions including Gastric Adenocarcinoma, Solid Tumor, Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma, Renal Tumor.
The trial portfolio spans Phase 2, EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — The First Affiliated Hospital with Nanjing Medical University
How many clinical trials has The First Affiliated Hospital with Nanjing Medical University sponsored?
ClinicalMetric currently tracks 14 clinical trials sponsored by The First Affiliated Hospital with Nanjing Medical University, of which 14 are actively recruiting participants. These trials cover conditions including Gastric Adenocarcinoma, Solid Tumor, Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does The First Affiliated Hospital with Nanjing Medical University research focus on?
The First Affiliated Hospital with Nanjing Medical University clinical trials span Gastric Adenocarcinoma, Solid Tumor, Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma, Renal Tumor, Prone Position, and additional conditions. The research pipeline includes Phase 2, EARLY_Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a The First Affiliated Hospital with Nanjing Medical University clinical trial?
To participate in a The First Affiliated Hospital with Nanjing Medical University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The First Affiliated Hospital with Nanjing Medical University trials with current recruitment status updated daily.
Clinical Trials by The First Affiliated Hospital with Nanjing Medical University
NCT07464756 Phase 2
Recruiting
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
Gastric Adenocarcinoma
NCT05166070 EARLY_Phase 1
Recruiting
An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
Solid Tumor
NCT07263386 Phase 2
Recruiting
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
Gastric Adenocarcinoma
NCT05931328 Phase 2
Recruiting
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
NCT06572501
Recruiting
Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position
Renal Tumor
NCT07110311
Recruiting
Impact of Pet Cats on Nasal and Gut Microbiota in Patients With Cat Allergen Allergy
Allergic Rhinitis
NCT07263425 Phase 2
Recruiting
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
Leptomeningeal Metastasis of HER2-positive Breast Cancer
NCT07050381
Recruiting
The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM
Arteriovenous Malformation of Central Nervous System
NCT06674187
Recruiting
Comparing the Incidence of Parastomal Hernia After Mesenteric Molding Suturing and Non-molding Suturing in Colostomy Surgery
Parastomal Hernia
NCT07455019 Phase 2
Recruiting
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
Esophageal Cancer
NCT05830136
Recruiting
Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy
Hepatic Ischemia
NCT07050537
Recruiting
A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology
Fertility Issues
NCT06543992 Phase 2
Recruiting
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis
Leptomeningeal Metastasis of Breast Cancer
NCT06715007
Recruiting
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
Stroke, Ischemic
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology